[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594629":3},{"organization":4,"armGroups":7,"interventions":36,"overallOfficials":49,"centralContacts":53,"locations":61,"responsibleParty":79,"collaborators":81,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":88,"sex":94,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":48,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":113,"whyStopped":48,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"University of Colorado, Denver","OTHER",[8,14,19,23,27,32],{"label":9,"type":10,"description":11,"interventionNames":12},"Pubertal Adolescent - Continuous Treatment","EXPERIMENTAL","Pubertal adolescents defined as Tanner stage 2-4 and\u002For 12-15 y\u002Fo who will receive 32 weeks of semaglutide (s.c.)",[13],"Drug: Semaglutide 1.7mg subcutaneous",{"label":15,"type":10,"description":16,"interventionNames":17},"Pubertal Adolescent - Early Treatment Cessation","Pubertal adolescents defined as Tanner stage 2-4 and\u002For 12-15 y\u002Fo who will receive 24 weeks of semaglutide (s.c.) followed by 8 weeks of placebo",[13,18],"Drug: Placebo",{"label":20,"type":10,"description":21,"interventionNames":22},"Post-Pubertal Adolescent - Continuous Treatment","Post-pubertal adolescents defined as Tanner stage 5 and\u002For 16-18 y\u002Fo who will receive 32 weeks of semaglutide (s.c.)",[13],{"label":24,"type":10,"description":25,"interventionNames":26},"Post-Pubertal Adolescent - Early Treatment Cessation","Post-pubertal adolescents defined as Tanner stage 5 and\u002For 16-18 y\u002Fo who will receive 24 weeks of semaglutide (s.c.) followed by 8 weeks of placebo",[13,18],{"label":28,"type":29,"description":30,"interventionNames":31},"Adult - Continuous Treatment","ACTIVE_COMPARATOR","Adults defined as 30-45 y\u002Fo who will receive 32 weeks of semaglutide (s.c.)",[13],{"label":33,"type":29,"description":34,"interventionNames":35},"Adult - Early Treatment Cessation","Adults defined as 30-45 y\u002Fo who will receive 24 weeks of semaglutide (s.c.) followed by 8 weeks of placebo",[13,18],[37,44],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"DRUG","Semaglutide 1.7mg subcutaneous","Semaglutide subcutaneous max dose of 1.7mg over 24 or 32 weeks of active treatment",[28,33,20,24,9,15],[43],"SEMA",{"type":38,"name":45,"description":46,"armGroupLabels":47,"otherNames":48},"Placebo","Placebo saline solution subcutaneous",[33,24,15],null,[50],{"name":51,"affiliation":5,"role":52},"Allison Shapiro, PhD, MPH","PRINCIPAL_INVESTIGATOR",[54,58],{"name":51,"role":55,"phone":56,"phoneExt":48,"email":57},"CONTACT","3037241150","allison.shapiro@cuanschutz.edu",{"name":59,"role":55,"phone":48,"phoneExt":48,"email":60},"Sean Nilan","thomas.nilan@cuanschutz.edu",[62],{"facility":63,"status":48,"city":64,"state":65,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":75},"University of Colorado Anschutz Medical Campus","Aurora","Colorado","80045","United States","US",{"type":70,"coordinates":71},"Point",[72,73],-104.83192,39.72943,{"lat":73,"lon":72},[76,78],{"name":51,"role":55,"phone":77,"phoneExt":48,"email":57},"303-724-3733",{"name":51,"role":52,"phone":48,"phoneExt":48,"email":48},{"type":80,"investigatorFullName":48,"investigatorTitle":48,"investigatorAffiliation":48,"oldNameTitle":48,"oldOrganization":48},"SPONSOR",[82,84],{"name":83,"class":6},"University of Minnesota",{"name":85,"class":6},"The Metis Foundation","100594629","phase-3-brain-plasticity-and-glp-1-receptor-agonist-treatment-for-obesity-100594629",false,"NCT07021937","Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity","Investigating Brain PLASTICity and GLP-1 Receptor Agonists in the Treatment of Obesity: The PLASTIC Trial","PLASTIC","Inclusion Criteria:\n\n* English-speaking\n* male or female (sex assigned at birth)\n* 12-18 y\u002Fo with obesity (BMI\\>120% of the 95th %ile)\n* 30-45 y\u002Fo with obesity (BMI\\>35 kg\u002Fm2)\n\nExclusion Criteria:\n\n* treated with glucagon-like peptide-1 (GLP-1) agonists (e.g., exenatide, liraglutide, semaglutide, tirzepatide) for weight management in the prior 3 months\n* currently taking anti-psychotic medications (anti-depressants accepted)\n* diagnosis of type 2 diabetes\n* current or lifetime anorexia nervosa or current bulimia nervosa\n* head injury resulting in loss of consciousness \\>30min\n* neurological disorder (e.g., Parkinson's disease) or history of stroke\n* any contraindication to receiving a MRI (e.g., orthodontal braces)\n* psychological\u002Fbehavioral dysfunction (e.g., autism spectrum disorder) or physical impairment that would interfere with study procedures, as determined by study physician\n* if female, desiring to become pregnant, or currently pregnant or breastfeeding","ALL","12 Years","45 Years",{"count":98,"type":99},120,"ESTIMATED","INTERVENTIONAL",[102],"PHASE3","Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults. However, despite this rapid adoption and the known GLP-1RA mechanism of action for weight loss, which targets brain circuits responsible for appetite and eating behaviors, almost nothing is known about how these drugs affect the brain in youth who are treated for obesity, or how these drugs affect the brain of youth differently from adults. The goal of the current study is to compare youth and adults with obesity who are treated a GLP-1RA and measure potential difference in GLP-1RA associated change in brain function, appetite, and eating behaviors.",[105],"Obesity\u002FTherapy",[107,108,109,110,111,112],"adolescent","adult","brain function","glucagon-like peptide-1 receptor agonists","eating behaviors","appetite sensations","NOT_YET_RECRUITING","2026-06-30",{"date":116,"type":117},"2026-07-02","ACTUAL",{"date":119,"type":99},"2026-06-15",{"date":121,"type":99},"2031-04-30",{"name":5,"class":6},1]